Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
LEIDEN, the Netherlands, Feb. 03, 2016 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA), today announced that Daniel de Boer, Chief Executive Officer, will take part in an analyst led fireside chat during the Leerink Global Healthcare Conference on Wednesday, February 10, 2016 at 2:15pm ET. The conference is being held at the Waldorf Astoria in New York, NY, USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.
Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
[email protected]
